Clean Science Q1 FY27 Earnings Call — Analysis (NSE: CLEAN)

Clean Science reports record quarterly sales of ₹264 Cr as HALS ramps to 22% of revenue and inks strategic pacts with Geneus and Kemin, though legacy volumes dip on supply-side headwinds.

6 Aug 2026 · Analysis by Alpha Inflection

The take

Q1FY27 Consolidated Revenue ₹264 Cr ( +10% YoY ) . New guidance — FY27 hals business ₹250–300 Cr . New story: HALS scale‑up and product‑mix upgrade .

Results

Consolidated revenue ₹264 Cr (+10% YoY); standalone revenue ₹203 Cr (-6% YoY) as supply disruptions hit volumes; standalone EBITDA margin 43%, PAT margin 36%; consolidated EBITDA ₹96 Cr (37% margin), PAT ₹73 Cr (28% margin).

Financial highlights

Guidance

FY27 HALS revenue targeted at ₹250–300 Cr (annualised).

What management committed to

• FY27 HALS revenue will reach ₹250–300 Cr, based on annualising the Q1FY27 run-rate. — ₹250–300 Cr, FY27
• The Geneus Chem partnership will add cumulative revenue of ₹300–350 Cr over the next 3–4 years from advanced NOR HALS. — ₹300–350 Cr, FY30
• Performance Chemical 2 plant will commence commercial production in Q3FY27 (November 2026). — Q3FY27
• First revenue from Performance Chemical 2 plant is expected from Q1FY28 after the stabilisation phase. — Q1FY28
• Kemin offtake will increase by 20–40% starting in the next 2–3 months (Q2FY27) under the new 5‑year agreement. — 20–40%, Q2FY27
• The Geneus collaboration plant will require a capex of approximately ₹25 Cr. — ₹25 Cr, FY27

Key themes

HALS ramp-up, strategic collaborations, and portfolio de-risking.

How the narrative shifted

• HALS scale‑up and product‑mix upgrade: Management positions HALS as the primary growth driver, with volumes, realisations and exports all accelerating, and product mix shifting to higher‑value grades.
• Strategic collaborations unlocking new markets: Geneus and Kemin pacts are framed as transformative, bringing patented advanced HALS and guaranteed volume offtake from a top‑tier customer, respectively.
• De‑risking of legacy business: The reduction in top‑4 legacy product concentration is highlighted as portfolio de‑risking, even as legacy volumes face temporary headwinds.
• Supply chain headwinds and raw material volatility: Geopolitical tensions, propylene shortages, shipping vessel unavailability and volatile RM pricing are repeatedly cited as external challenges that constrained volumes and margins.
• Capacity expansion to drive next leg of growth: PC2, hydroquinone/catechol, and the new Geneus plant represent a capex cycle that management expects to convert into revenue from FY28, though near‑term delays are acknowledged.
• Margin resilience from HALS operating leverage: Management signals that HALS EBITDA margins should expand with higher‑grade mix and operating efficiencies, providing a buffer against RM volatility.

Operational commentary

• HALS volumes reached ~1,000 tons in Q1; product mix shifted to higher grades (770 share fell from 50% to ~35%), lifting average realisations from ₹440 to ₹550/kg and improving gross margins.
• HALS exports surged to ~50% of HALS revenue (vs 0% domestic-only first year), driven by customer approvals for all grades and now enabling cross-selling across the HALS portfolio.
• Entered strategic collaboration with Geneus Chem for patented advanced NOR HALS; tech transfer underway, plant start Q3FY27; cumulative revenue target ₹300–350 Cr over the next 3–4 years, targeting a market dominated by BASF.
• Signed 5-year exclusive supply agreement with Kemin, the world’s largest buyer of food/feed antioxidants (BHA, BHT, TBHQ, AP), securing volume offtake; Kemin volumes to increase 20-40% starting Q2FY27, requiring additional capacity.
• Hydroquinone and catechol plant stabilised; customer approvals received; commercial supplies to ramp from August–September 2026, with gradual revenue build expected.
• Performance Chemical 2 delayed by labour issues; commercialisation now expected in November 2026 (Q3FY27), stabilisation through March 2027, first meaningful revenues from Q1FY28.
• Portfolio derisking: top-4 legacy products reduced to 60% of standalone revenue from 85% in Q4FY23, lowering concentration risk.
• Standalone legacy volumes hit by ~2‑week shutdown (propylene shortage) and shipping vessel non‑availability; demand steady, supply availability since improved.
• Clean Fino Chem became operationally self‑sustaining; all future new products and expansions to be housed in this subsidiary; ₹100 Cr capital infused in Q1, total ₹850 Cr.

Analyst Q&A

• Q. What is the realistic HALS revenue number for FY27?

  Annualized this quarter is ₹250-300 Cr. So FY27 HALS revenue should reach ₹250-300 Cr.

• Q. Details on Geneus Chem partnership — is it distribution or tech transfer, and what does Clean Science pay?

  It’s a tech-driven partnership; tech transfer for patented advanced NOR HALS with no fees; joint marketing and geographic split.

• Q. Will HALS export ramp and higher-grade shift sustainably boost EBITDA margins?

  EBITDA margins will keep improving as we move to higher-grade products and operational efficiencies kick in.

• Q. Can we get confirmation that supply chain issues won't cause production stoppages going forward?

  I'm not so confident that it is locked. Nobody can control.

View source

Research and educational content only. Not investment advice.